An article published on Calcalist, in collaboration with FLORA Ventures, introduces Lembas, a food company developing a functional ingredient designed to increase the feeling of fullness. The technology was developed at the Faculty of Medicine at Tel Aviv University, using an AI-based computational biology approach to screen peptides.
The company’s first peptide targets GLP-1, the satiety hormone, at a lower dose than medications do and, according to the company, is not classified as a drug. Gil Horsky, co-initiator and founding chairman of Lembas, explains that the goal is to make weight management more accessible, starting with food supplements and later moving into products such as snacks and shakes. The company has raised more than $5 million, led by Horsky’s fund. Read the full article on Calcalist.